Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

FDA, EU Need Common Adverse Reaction Definitions, Lilly’s Simmons Says

Executive Summary

FDA and European regulators should adopt a common definition for what adverse reactions must be reported, Lilly Global Product Safety Advisor Valerie Simmons, MD, said

You may also be interested in...



Adverse Event Reports Should Be 80% Electronic By Year End, FDA Hopes

FDA hopes to receive 80% of adverse event reports in electronic format by the end of the year, CDER Division of Drug Risk Evaluation Associate Director Min Chen said

Adverse Event Reports Should Be 80% Electronic By Year End, FDA Hopes

FDA hopes to receive 80% of adverse event reports in electronic format by the end of the year, CDER Division of Drug Risk Evaluation Associate Director Min Chen said

FDA Drug Safety Rule Would Promote Premarketing Adverse Event Reports

FDA's proposed definition of "suspected adverse drug reactions" would encourage more premarketing adverse event reporting

Latest Headlines
See All
UsernamePublicRestriction

Register

PS043167

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel